A5060265024- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Melanoma and MAPK Pathways
- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Peptidase Inhibition and Analysis
- Lung Cancer Research Studies
- Protein Degradation and Inhibitors
- Click Chemistry and Applications
- Autophagy in Disease and Therapy
- Brain Metastases and Treatment
- Histone Deacetylase Inhibitors Research
- Colorectal Cancer Treatments and Studies
- Neuroendocrine Tumor Research Advances
- Synthesis of Tetrazole Derivatives
- Metabolism, Diabetes, and Cancer
- Lung Cancer Treatments and Mutations
- Advanced Biosensing Techniques and Applications
- Epigenetics and DNA Methylation
- Pancreatic function and diabetes
- Cancer-related molecular mechanisms research
- Immune Cell Function and Interaction
Fujian Provincial Cancer Hospital
2022-2025
Fujian Medical University
2022-2025
Fuzhou University
2024
Roche (China)
2023
Neoantigens are ideal targets for dendritic cell (DC) vaccines. So far, only a few neoantigen-based DC vaccines have been investigated in clinical trials. Here, we reported case of patient with metastatic gastric cancer who received personalized neoantigen-loaded monocyte-derived (Neo-MoDC) followed by combination therapy the Neo-MoDC and immune checkpoint inhibitor (ICI). The developed T responses against neoantigens after receiving vaccine alone. following triggered stronger response...
Anti-programmed cell death-1 monotherapy is part of standard therapy for cutaneous melanoma but has low efficacy in mucosal melanoma. We evaluated the and safety atezolizumab plus bevacizumab as first-line advanced melanoma.This multicenter, open-label, single-arm, phase II study used a Simon's two-stage design. Atezolizumab (fixed-dose, 1,200 mg) (7.5 mg/kg) were administered by intravenous infusion every 3 weeks. The primary endpoint was objective response rate (ORR), determined per RECIST...
Atezolizumab plus bevacizumab has shown promising efficacy in advanced mucosal melanoma the multi-centre phase II study. This report updates 3-year survival outcomes and multi-omics analysis to identify potential response biomarkers.
9562 Background: Despite great success of immunotherapy (IO) in advanced melanoma, there remains unmet clinical needs for IO resistant and cold tumors. IBI363 is a first-in-class PD-1/IL-2 α -bias bispecific antibody fusion protein which could block PD-1 checkpoint activate α-bias IL-2 to rejuvenate exhausted tumor-specific T cells. Herein, we report updated results from the phase I study evaluate safety efficacy pts with melanoma. Methods: Eligible melanoma who failed or intolerant standard...
Acral melanoma, the most common subtype of melanoma in Asians, is often diagnosed at an advanced stage and responds poorly to current programmed cell death protein 1 (PD-1) inhibitors.
Immunogenic cell death (ICD) is a type of regulated that can activate adaptive immune response, and its ability to reshape the tumor microenvironment via multiple mechanisms may contribute immunotherapy. The treatment options for patients with skin cutaneous melanoma (SKCM) vary based on BRAF V600E statuses. However, all standard treatments include Therefore, it critical identify ICD‐associated signatures help classify according benefits from ICD In this study, data samples mutation (BRAF...
9510 Background: NRAS-mutant melanoma is an aggressive subtype with worse prognosis. However, no targeted therapy has been approved to date worldwide. Tunlametinib (HL-085), a novel, potent, selective, oral small-molecule MEK1/2 inhibitor, showed favorable pharmacokinetics profile, acceptable tolerability and encouraging antitumor activity in the phase 1 study (BMC Med. 2023 Jan 4;21(1):2). Methods: This ongoing, multicenter, open-label, single-arm, 2 pivotal registration study. Patients...
Cutaneous melanoma (CM) is an aggressive form of skin cancer with limited treatment options for advanced stages. Prognostic markers that accurately predict patients' outcomes and guide therapeutic strategies are crucial improving management. SETD2 (SET Domain-Containing Protein 2), a histone methyltransferase involved in chromatin remodeling gene regulation, has recently emerged as tumor suppressor. Its dysfunction oncogenesis some cancers, but little known about its functions progression...
Patients with malignant melanoma brain metastases (MBMs) have poor prognoses. For MBMs, the Melanoma-molGPA is most widely used predictive score, but its value remains uncertain in patients fully treated radiotherapy. We identified MBMs prognostic factors and modified scoring model.We retrospectively analyzed diagnosed between December 2010 November 2021 for influencing overall survival (OS) by univariate multivariate analyses. Nomogram plots were based on Cox regression modeling. evaluated...
3095 Background: In phase 1A dose-escalation study, preliminary anti-tumor activity of FCN-159 was observed in advanced melanoma patients harboring NRAS mutations (ORR: 19.0%, mPFS: 3.8 months) with tolerable safety profile, which posted during AACR 2022 (No.: 22-LB-7398-AACR). Here, we report the results from 1B dose-expansion study NRAS- or NF1-mutant at RP2D predetermined 12 mg. Methods: This open-label, dose-expansion, (NCT03932253) consists two cohorts, enrolled unresectable stage...
Dysregulated metabolism in tumor tissues, and para-tumor tissues alike, can lead to immunosuppression, which may underlie cancer development. However, metabolic intervention as a therapeutic strategy has been of no avail. In this study, we explored the anti-cancer effect aldometanib that specifically targets lysosome-associated aldolase mimic glucose starvation thereby activates lysosomal AMP-activated protein kinase (AMPK), master regulator homeostasis. We show inhibits growth HCC an...
<div>AbstractPurpose:<p>Anti–programmed cell death-1 monotherapy is part of standard therapy for cutaneous melanoma but has low efficacy in mucosal melanoma. We evaluated the and safety atezolizumab plus bevacizumab as first-line advanced melanoma.</p>Patients Methods:<p>This multicenter, open-label, single-arm, phase II study used a Simon's two-stage design. Atezolizumab (fixed-dose, 1,200 mg) (7.5 mg/kg) were administered by intravenous infusion every 3 weeks. The...
<div>AbstractPurpose:<p>Anti–programmed cell death-1 monotherapy is part of standard therapy for cutaneous melanoma but has low efficacy in mucosal melanoma. We evaluated the and safety atezolizumab plus bevacizumab as first-line advanced melanoma.</p>Patients Methods:<p>This multicenter, open-label, single-arm, phase II study used a Simon's two-stage design. Atezolizumab (fixed-dose, 1,200 mg) (7.5 mg/kg) were administered by intravenous infusion every 3 weeks. The...
Supplementary Figure from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
Supplementary Figure from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
Supplementary Data from Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study